Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.57 |
| ▸ | CCND1 | P24385 | 5/20 | 0.57 |
| ▸ | CCND2 | P30279 | 1/20 | 0.57 |
| ▸ | CCND3 | P30281 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 12/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519312 | 0.88 | CDK4 (0.56) | CDK4CCND1CCND2CCND3SYK | |
| SCHEMBL5512844 | 0.87 | RPS6KA6 (0.49) | CDK4CCND1CCND2CCND3CCNE1 | |
| SCHEMBL5520417 | 0.87 | CDK4 (0.59) | CDK4CCND1CCND2CCND3SYK | |
| SCHEMBL5525641 | 0.87 | RPS6KA6 (0.61) | CDK4CCND1CCND2CCND3CCNE1 | |
| SCHEMBL27582218 | 0.81 | CDK4 (0.53) | CDK4CCND1CCND2CCND3SYK | |
| SCHEMBL5514445 | 0.81 | CDK4 (0.44) | CDK4CCND1CCND2CCND3CCNE1 | |
| SCHEMBL3972021 | 0.80 | CDK4 (0.57) | CDK4CCND1CCND2CCND3SYK | |
| SCHEMBL5523371 | 0.80 | BRD4 (0.42) | CDK4CCND1CCND2CCND3CCNE1 | |
| SCHEMBL29055819 | 0.78 | CDK4 (0.55) | CDK4CCND1CCND2CCND3SYK | |
| SCHEMBL7715488 | 0.76 | RPS6KA6 (0.64) | CDK4CCND1CCND2CCND3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | claimed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | claimed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | CDK4 5/4885CCND1 32/4885CCND2 31/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | CDK4 5/4885CCND1 21/4885CCND2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.